Newsroom | Vertex Pharmaceuticals Newsroom
Vertex to Announce Third Quarter 2024 Financial Results on November 4th. Read More. Sep262024. Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference. Read More.
Press Release - Vertex Pharmaceuticals Newsroom
Dec 8, 2023 · Vertex leads global development, manufacturing and commercialization of CASGEVY with support from CRISPR Therapeutics. In conjunction with the FDA approval of CASGEVY, Vertex will make a $200 million milestone payment to CRISPR, which will be capitalized and amortized to cost of sales.
Press Releases - Vertex Pharmaceuticals Newsroom
Aug 7, 2024 · Vertex to Announce Second Quarter 2024 Financial Results on August 1. BOSTON -- (BUSINESS WIRE)--Jul. 1, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2024 financial results on Thursday, August 1, …
Press Release - Vertex Pharmaceuticals Newsroom
Mar 21, 2024 · VX-407 is a first-in-class small molecule corrector that is designed to target the underlying cause of ADPKD in a subset of patients with PKD1 variants, estimated at ~25,000 (or ~10%) of the overall ~250,000 ADPKD patient population, …
Press Release - Vertex Pharmaceuticals Newsroom
Apr 10, 2024 · Vertex Enters Into Agreement to Acquire Alpine Immune Sciences. - Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies -. - Alpine’s lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 -.
Press Release - Vertex Pharmaceuticals Newsroom
Jan 30, 2024 · Vertex plans to submit a New Drug Application to the Food and Drug Administration (FDA) by mid-2024 with the goal of achieving a broad label in moderate-to-severe acute pain. VX-548 has secured Breakthrough Therapy and Fast Track designations in …
Press Release - Vertex Pharmaceuticals Newsroom
Oct 3, 2023 · VX-264 is an investigational cell therapy in which allogeneic human stem cell-derived islets are encapsulated in a channel array device designed to shield the cells from the body’s immune system. VX-264 is designed to be surgically implanted and is currently being evaluated for patients with T1D.
Corporate Images - Vertex Pharmaceuticals Newsroom
Vertex Headquarters – Boston Seaport. Exterior of Vertex headquarters in Boston, MA.
Press Release - Vertex Pharmaceuticals Newsroom
Apr 1, 2024 · Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease. – 45 mg once daily oral dose selected for Phase 3 –. – Results support trial expansion to lower age group and study will now include adolescents ages 10-17 years –. – If positive, pre-planned ...
Press Release - Vertex Pharmaceuticals Newsroom
Apr 23, 2024 · TreeFrog and Vertex will collaborate to scale-up TreeFrog’s process to produce and amplify cells for Vertex’s T1D therapies. TreeFrog’s proprietary technology platform, C-Stem™, is designed to mimic the natural microenvironment, allowing cells to …
- Some results have been removed